Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VHB937 in early Alzheimer's disease
CTR20254088Phase 2Active
- Sponsor
- Novartis
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of VHB937 in Alzheimer's disease (AD), sponsored by Novartis. Started Nov 2025; status: active.
02
Drugs
VHB937
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on CTR20254088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20254088.